Pharmacological advances of alkaloids from Traditional Chinese Medicine against pulmonary fibrosis: focus on anti-inflammatory mechanisms.
文献摘要
Pulmonary fibrosis (PF) is a fatal respiratory disease characterized by abnormal repair of the pulmonary interstitium and scar formation. Currently, only nintedanib and pirfenidone are approved for clinical use, but their efficacy is limited, and they have significant side effects. The sustained inflammatory microenvironment promotes fibroblast activation and collagen deposition via unresolved inflammation, representing a central pathological mechanism in PF progression. Therefore, anti-inflammatory effects are key in relieving and treating PF. Alkaloids derived from Chinese herbal medicine have become a new hotspot in anti-PF research because of their good anti-inflammatory properties and advantages in multitarget and multipathway approaches. This review elucidates that PF is triggered by multiple factors, such as genetics, the environment, drugs, and infection, and reveals the core mechanism of its pathogenesis from the perspective of the roles of various cell types involved in PF. In this review, we focus on the experimental efficacy and mechanisms of alkaloid drugs that mitigate pulmonary fibrosis through anti-inflammatory actions. We review the research progress of experimental models and signaling pathway regulatory mechanisms to provide a reference for subsequent research. Finally, this review analyzes the transformation bottlenecks faced by alkaloids when applied to PF, such as low active ingredient content, poor target selectivity, and insufficient toxicological and clinical data. Strategies such as structural optimization, nanodelivery, multiomics validation, and real-world research are proposed to overcome these challenges, providing a reference for the development of highly efficient and low-toxicity anti-PF drugs.